At the 2026 Annual General Meeting of BRAIN Biotech AG, shareholders approved all agenda items with a broad majority, demonstrating strong support for the company's strategic direction. The meeting, which represented 61.82% of the share capital including postal votes, marked a significant moment for the biotechnology company as it continues to execute its growth strategy in specialty enzymes and biotechnological solutions.
Dr. Ursula La Cognata of Berlin, the managing partner of ybe (Your Biotech Experts Partnership), was elected to the Supervisory Board by the Annual General Meeting for a term of four years. She had previously been appointed by the Darmstadt Local Court as a new member of the Supervisory Board, effective 11 July 2025, until the next Annual General Meeting. This appointment brings additional expertise to the company's governance structure as it navigates the competitive biotechnology landscape.
In his statement to shareholders, Supervisory Board Chairman Dr. Michael Majerus emphasized the company's positive development opportunities, stating: "We remain convinced that BRAIN Biotech AG has many positive development opportunities thanks to its successful product business, its strong market position in contract research, the expected revenues from the monetization initiatives as well as licensing of pharmaceutical projects, and further product innovations from the BRAINBioIncubator." This outlook reflects confidence in the company's diversified approach to biotechnology development and commercialization.
CEO Adriaan Moelker elaborated on the company's strategic direction during his speech, affirming: "We remain convinced that our two-pillar strategy, with the product-oriented BRAINBiocatalysts segment on the one hand and the BRAINBioIncubator segment on the other, is the right strategy. This approach enables us to continue to monetize our investments, achieve scientifically based breakthroughs, and organically expand a profitable, scalable, enzyme-focused business." This dual approach allows the company to balance immediate revenue generation with long-term research and development initiatives.
Moelker highlighted the company's agility as a key competitive advantage, noting that due to its relatively small size, BRAIN Biotech can respond quickly and flexibly to customer needs with short communication channels and offer innovative biotechnological solutions. The CEO emphasized the importance of maintaining this advantage even as the company experiences stronger growth in the future, suggesting that operational efficiency and customer responsiveness remain priorities despite expansion plans.
The company reported progress on its operational consolidation, with Moelker detailing the consolidation of production and sales for enzymes and food ingredients for the baking and beverage industries at the new location in the Netherlands. The new building, which will house a modern baking application center, a laboratory, and production areas, is nearing completion. This infrastructure development supports the company's position as a leader in researching, developing, and producing specialty enzymes, with a focus on the food and life sciences industries.
The detailed voting results and all other documents relating to the 2026 Annual General Meeting are available on the BRAIN Biotech AG website. For more information about the company's operations and business segments, visit www.brain-biotech-group.com.
BRAIN Biotech AG operates its own fermentation facilities in the UK and has additional production sites in continental Europe and the US. The company has been listed on the Frankfurt Stock Exchange since February 9, 2016 (Ticker symbol: BNN; ISIN: DE0005203947 / WKN: 520394). In the 2024/25 fiscal year, the group generated revenue of €49.6 million with around 280 employees, demonstrating its growing presence in the biotechnology sector. The company's activities are divided into two business segments: BRAINBiocatalysts, which focuses on development, production, and distribution of specialty enzymes, microorganisms, and ingredients; and BRAINBioIncubator, which handles research-intensive development projects and pharmaceuticals.
The shareholder approval of all agenda items at the Annual General Meeting signals confidence in the company's leadership and strategic direction. As biotechnology continues to play an increasingly important role in developing sustainable products and efficient processes across multiple industries, BRAIN Biotech's focus on specialty enzymes and customized biological solutions positions it to address growing market demands. The company's ability to maintain operational agility while pursuing growth initiatives will be crucial as it competes in the dynamic biotechnology landscape, where innovation speed and customer responsiveness often determine market success.
